electroCore, Inc. (ECOR) Earnings Call Transcript & Summary

August 6, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 61 min

Earnings Call Speaker Segments

Thomas Errico

executive
#1

Thanks, operator. Good afternoon, everybody, and thanks for being on electroCore's Second Quarter 2026 Earnings Call. It's great to have another chance to talk with all of you about the transformation and momentum taking place at electroCore. In my role as Chairman of the Board, I've worked closely throughout the quarter with Josh Lev, Interim President, and Mike Fox, COO. Josh has kept the company steady and focused while handling Investor Relations with real skill, and Mike has acted fast to implement key operational changes, among them a significant overhaul of our sales force. Change is never simple, and steering change without disruption demands genuine skill. Today, I can say with pride that Josh and Mike have helped us implement meaningful changes while keeping the organization advancing. You'll hear the results shortly, but electroCore has entered a new phase, one characterized by accelerating revenue growth and improving operating leverage. Today, we are raising our 2026 revenue guidance to greater than 30%, and we're doing that while demonstrating better profitability, with GAAP net loss for the quarter improving by 17% to $3.1 million from $3.7 million in the prior year, and adjusted EBITDA improving 26% year-over-year and 25% sequentially. This progress occurred as we intentionally invested approximately $1 million in the quarter on initiatives meant to speed up future growth; we now think this trajectory places us on a path toward positive EBITDA in 2027. To me, that's what disciplined execution looks like: putting money into durable growth opportunities while remaining disciplined and holding the line on spending everywhere. The Board is very pleased with the competency, discipline and leadership Josh and Mike have shown in delivering this execution. Our strategy hasn't changed. What has changed is the pace and precision with which we're executing it, and that mirrors the leadership Josh and Mike are providing across the company. With that, Josh will give opening remarks. Mike will take you through the operational specifics, and then Josh will walk you through the quarter and where we go from here. With that, I'd like to turn it over to Josh.

Josh Lev

executive
#2

Thanks, Tom. Good afternoon, everybody. This quarter opened a brand-new chapter for the company, since we rolled out major changes throughout our commercial organization, which we think will set us up better for success over the long haul while also lifting our reported financial results. Those changes covered growing our sales territories, bringing on additional reps, and reworking our incentive plan so that accountability and cost efficiency improve with time. These moves demanded investment and attention during the quarter, but we're confident they've shored up our foundation, boosted operating efficiency, and sharpened our capacity to speed up revenue growth. I'll hand things to Mike shortly so he can detail the execution further. Now, on to the quarter's results. Quarterly revenue came in at $9.5 million, up roughly 28% versus the prior-year period, powered by ongoing gains in U.S. prescription sales within the VA as well as direct-to-consumer Truvaga sales. Because we restructured during this quarter, these results feel particularly heartening given how large the organizational changes were. Revenue held steady from one quarter to the next, yet we anticipate growth will pick up speed as the year goes on, supported by orders we've already booked that haven't yet shown up in revenue, which Mike will address later in the call. Notably, we delivered ongoing operating leverage, as seen in the steady gains in adjusted EBITDA, which rose 26% compared with a year ago and 25% versus the prior quarter. We see this as a real victory, showing how resilient our business is and how well we can execute while setting the company up for profitable growth over the long term. The changes we made in the second quarter are already paying off; and with the momentum we're witnessing across the business, we're lifting our full year 2026 revenue guidance to greater than 30% growth over full year 2025 revenue. As Dr. Errico noted, we think the operating improvements we've described today put us in position to carry out our plan of reaching positive adjusted EBITDA in the third quarter of 2027. Moving to the portfolio. The VA remained our biggest growth engine this quarter. Prescription gammaCore revenue climbed approximately 11% from a year earlier, and roughly 16,400 VA patients have now gotten the gammaCore device, which works out to about 2.7% penetration of the estimated addressable VA headache market. When we bought NeuroMetrix last year, we brought two Class II medical devices into our portfolio. The first one, Quell Fibromyalgia, is presently marketed as a prescription therapy via the VA. The second, Quell 2.0, is an FDA-cleared over-the-counter device aimed at lower extremity pain. Right now it isn't in production or available for purchase, and we might rebrand and relaunch it direct-to-consumer down the road. When we made the acquisition, we spotted the chance to offer a technology distinct from gammaCore, sold via those same VA relationships, the same reps, the same call points, simply a new product to sell. Since completing the acquisition, Quell has turned into a standout within our product portfolio. Sales for the Quell product line reached $1.3 million in the second quarter, up approximately 700% from a year earlier and about 30% from the first quarter of 2026. All told, we've brought in roughly $4 million from Quell since purchasing NeuroMetrix back in May 2025. Of that figure, $3.8 million comes from Quell Fibromyalgia sales into the VA. We see Quell Fibromyalgia as an ongoing major opportunity for us. An article in Rheumatology Advisor noted that among U.S. service members, Fibromyalgia prevalence went from 2.2% for men and 2% for women prior to deployment up to 8% and 11.1% afterward. That steady pattern, especially with Fibromyalgia, backs up our belief in delivering non-invasive bioelectronic therapeutics to patients who need alternatives to pharmaceuticals. Our over-the-counter wellness brand, Truvaga, climbed about 27% year-over-year, reaching $1.3 million. Competition in health and wellness pushed media costs higher, which raised customer acquisition costs and pulled our media efficiency ratio down to 1.91. During the first half of 2025, five rivals bid on Truvaga's own branded search terms. By the first half of 2026, that number had risen to eight — a 60% jump in the count of ads appearing on the very terms that ought to be Truvaga's safest ground. Consequently, the direct cost per click for acquiring a customer went up by about 30%. Because advertising in this space got more expensive, we cut media spend by 2% during the quarter, which let us spend less while still achieving year-over-year Truvaga growth. In our first quarter of 2026 10-Q, we disclosed that on May 5, 2026, FDA personnel came to our Rockaway, New Jersey facility to inspect matters tied to a follow-up 2017 inquiry concerning our wholly owned subsidiary, NeuroMetrix. The FDA wrapped up that inspection on May 27, 2026, and handed the company a preliminary 483 letter, which listed four observations and two discussion points regarding how we handle and document patient complaints. After getting that letter, we replied to the preliminary 483 with corrective actions addressing the observations and discussion points. Those corrective actions will push back the possible rebrand and relaunch of Quell 2.0 direct-to-consumer in the near term, though in the end we expect these changes to produce a stronger product and brand, putting us in position to update our claims down the road so they better capture the wider benefits of a newly branded product. At this point I'd like to hand the call to Mike, who will walk through some of the specific changes made during the quarter. Mike?

Mike Fox

executive
#3

Appreciate that, Josh. Good afternoon to all of you. When we held our previous earnings call, I had just completed three weeks in my new role. Now that I've got close to four months behind me, my confidence has only grown that electroCore is set up to deliver speeding-up revenue growth with better predictability and improved profitability. What drives that conviction is the headway we've made on three main priorities, the same ones I laid out on my first earnings call: broadening VA Medical Center reach, deepening how much product gets used inside each VA, developing the wider federal channel, and running the business on strong operating principles as we grow. I'd like to take you through where each one stands right now. Starting with our sales organization. We looked at how our team was built relative to how big the opportunity is, and the answer came through loud and clear; we had to follow a definite plan to widen coverage and establish unambiguous accountability across the sales team. We increased our sales regions to twice the prior count and reorganized our regional sales directors around that fresh structure, which delivers sharper focus and better leadership across smaller territories, enabling our RSVs to mentor, guide and grow advocacy in the areas they're responsible for; that sharper focus hands us a huge chance to boost customer value, strengthen patient advocacy and get a bigger return on investment from what our sales team does. In parallel, we brought on, signed up and put through training 17 additional 1099 sales representatives, and they now serve 29 VA medical centers; that works out to roughly 20% of the VAMC network nationwide. I want to be clear, these new 1099s aren't newcomers to the VA marketplace or to selling medical devices. They rank among the most capable, highest-achieving sales people you can find in the American market. I've spent time personally with each of these new colleagues, and I can tell you they've all established legacies in their accounts and with their customers thanks to many years of committed, first-rate customer service that produced top-tier results. Bringing them aboard marks the biggest quarterly addition of sales colleagues in our history, and it demonstrates not just that we're committed to strengthening every role and every process at electroCore, but also that the best people want to be part of our mission. In the brief period since these new 1099s came on, we've unlocked new VA accounts and grown the count of new prescribers, which amounts to real expansion of our presence across VA and Department of Defense accounts, precisely the federal channel we identified as offering the biggest opportunity and needing deeper penetration; these additions will also help spread our revenue across more facilities, since at present our top 15 accounts generate 54% of our Q2 VA revenue. Spreading things out like this matters for reducing concentration risk, where a handful of large facilities, even if few in number, account for a substantial share of revenue. So in the second quarter of 2026, a staffing problem arose at one of our locations in the prosthetics department. That left about 30 orders unable to be fulfilled, and although those prescriptions were written in Q2 2026, they were actually filled and completed in July, which shifted around $145,000 of revenue into Q3 2026. That revenue wasn't lost — we recorded it during the current quarter — but it highlights why we need to broaden the number of sites that sell and fulfill our prescription products, so that a single location can't have such a dramatic impact on our metrics. We're also staying rigorous about how we track and drive that expansion; our KPIs have been updated to center on performance dashboards, which lets us monitor new patients and refill rates at the level of each individual VA account, so we can build a pipeline of future scripts and concentrate on lifting our refill rate by 30% across every region before 2026 ends. To ensure this newly expanded team delivers, we've also reworked our sales incentive compensation plan to set a higher bar for expectations and accountability. We added a dedicated recruiter whose only responsibility is to fill vacant or underperforming VA territories with proven sales talent. That effort, together with the skilled sales professionals who reach out to us directly asking to come aboard, will keep making our team and our results stronger. These adjustments are also designed so that our cost efficiency improves over time. Reworking our incentive plan to reward sustained account-level growth instead of end-of-quarter volume should, once it takes hold, lower the sales and marketing expense tied to every dollar of revenue; and realigning territories is meant to remove overlapping, inefficient coverage that drove up costs without creating lasting accounts. Because we'll no longer pay commission to overlapping sales colleagues, we anticipate incentive compensation variable expense dropping from roughly 35% of prescription revenue to roughly 27% by the close of 2027, along with a decline in overall sales and marketing expense to roughly 54% by the close of 2027 under the new cost structure and territory alignment. Outside the VA, we also made two targeted federal hires during this quarter. We brought on a 1099 representative tasked specifically with expanding our footprint in the Kaiser market beyond California, and we brought in a W-2 employee to provide dedicated focus and expertise for Department of Defense and Federal Workers Compensation — two channels we've previously described as underdeveloped relative to their potential. One of the more structurally significant steps this quarter came on the contracting front. Going forward, Lovell Government Services will serve as the sole federal supply schedule contract holder for all electroCore products in the VA and Department of Defense markets alike. That streamlines how our products travel through federal procurement and puts us in position to scale federal growth more efficiently; it will additionally trim about 3% of our General & Administrative expenses along with the transaction fees tied to direct sales. By the close of this month—August 2026—every federal order going through Lovell will have made that switch. We've also got consultants lined up, with contracts in the final stages, to drive advocacy and revenue, particularly around the opportunities we've pinpointed in first responders, the Department of Defense, and the Departments of Women Health within the VA. A member of our own Board has been involved directly with the women's health initiative, and the early alignment we're seeing there encourages us. Turning to TAC-STIM, our efforts focus on uptake beyond active duty military and on widening the pipeline of prospective customers. We're taking part in a study assessing TAC-STIM during the annual SWAT Training Academy, which is set for November of this year. Another state police department is now working with us on a SWAT team evaluation, along with other chances to support our first responders in what they do day to day. Beyond that, utilization has grown, as reflected in the units bought and distributed by a range of domestic law enforcement and U.S. intelligence agencies. Last, on marketing and enablement: we brought on a marketing director who brings extensive VA training and marketing experience, and for our current and expanded sales colleagues we're creating a fresh training and onboarding curriculum, set to launch this quarter in 2026. At the same time, marketing is widening provider-facing access to the considerable body of our published clinical trials and data sets, while refreshing our materials so they align more closely with what our customers and the patients we focus on actually need. In the end, this quarter centered on building and growing the infrastructure, people, contracts, data and process; that converts the stated strategy of market and specific facility depth into something measurable. Early signs of success are appearing, and we expect this impact to grow over time as business progress turns into greater financial impact. I have confidence in the foundation now in place and the actions we carried out across the last 90 days. As a company, we are stronger and have laid out the blueprint for consistent and sustainable growth. I'm eager to share more results and KPI metrics as the data develops in the months ahead. With that, I'll hand it back to Josh to walk through the financials. Josh?

Josh Lev

executive
#4

Thanks, Mike. For the quarter that closed on June 30, 2026, electroCore posted net sales totaling $9.5 million, versus $7.4 million across the equivalent stretch of 2025 — a gain of roughly 28% year over year. That $2.1 million bump came mainly from higher net sales of the Quell Fibromyalgia products we picked up from NeuroMetrix in May 2025, plus prescription gammaCore, which goes to the VA, along with continuing gains in net sales for Truvaga, our non-prescription general wellness offering. Management anticipates that most of fiscal 2026 revenue will be generated by the VA. Gross profit rose $1.7 million, reaching $8.2 million for the three months that ended June 30, 2026, up against the three months that ended June 30, 2025. Higher net sales account for that gross profit improvement. Gross margin slipped to 86.5% from 87.3% across the three months that ended June 30, 2026, versus the three months that ended June 30, 2025. A larger inventory reserve was the main reason for that modest margin decline. Research & Development expense came in at $800,000 during 2026's second quarter, up from $500,000 during 2025's second quarter. More studies and grants, greater stock-based compensation, and initial spending to build enhancements for our Truvaga mobile application largely explain that rise. For the three-month period that wrapped up on June 30, 2026, Selling, General & Administrative Expense came in at $10.1 million, compared with $9.4 million during the same stretch last year. Sales & Marketing rose by $1.4 million year over year. About $900,000 in variable costs associated with backing the $2.1 million improvement in net sales accounted for that bump in sales and marketing, which highlights how much operating leverage the company's platform contains as it grows. Meanwhile, General & Administrative expense was down $700,000 relative to the prior year. That decline stemmed mostly from $500,000 of bad debt expense tied to the tax and receivable booked during the three months that ended June 30, 2025, which did not recur in 2026, plus lower professional fees during the three months that ended June 30, 2026. Total operating expenses for the three months that ended June 30, 2026, were $10.9 million, versus $9.9 million across the three months that ended June 30, 2025. GAAP net loss during 2026's second quarter was $3.1 million, versus $3.7 million during 2025's second quarter. That smaller GAAP net loss came mainly from stronger gross profits tied to the net sales increase, partly offset by variable sales and marketing expenses connected to those higher net sales. For the second quarter of 2026, we reported a net loss per share of $0.33. That compares with a net loss per share of $0.44 in the same quarter of 2025. On an adjusted EBITDA basis, our net loss for 2026's second quarter came to $1.8 million, compared with a net loss of $2.4 million in 2025's second quarter. That's an improvement of roughly $600,000, or 26%, in the year-over-year loss. When we look at June 30, 2026, our total cash, cash equivalents and marketable securities were approximately $10 million, compared with about $11.6 million as of December 31, 2025. During this quarter we saw the initial infrastructure modifications Mike described, among them broader sales territories, a larger sales force, and an emphasis on new KPIs that propel durable growth — which gives us the confidence to lift our earlier guidance to above 30% annual growth for the entirety of 2025. According to the model we currently use, our aim is positive adjusted EBITDA by the third quarter of 2027, and we think that goal is achievable with the capital resources we already hold, with no need for a dilutive capital raise or further equity issuances, provided the operating leverage just described materializes. Strategy deserves a moment of my time, since it shapes everything about how we approach this business. What we're describing now is a different story: electroCore has become a platform in bioelectronic medicine with multiple catalysts, rather than a narrative built on one product and one customer. Going forward, every quarter we'll track and report on 3 catalysts. I'll quickly walk through what's ahead in the second half of the year. First is Research & Development, where we go after new prescription indications. More than 30 investigator-initiated trials are underway in a range of therapeutic areas, and they cost the company nothing directly, while at the same time we're deepening the clinical evidence behind vagus nerve stimulation. First, on CIPN—that's chemotherapy-induced peripheral neuropathy—we're working toward filing with the FDA, using our Quell product, and we're aiming to wrap that up before the year ends, assuming the analysis currently underway comes through. Second, alongside the Dorn Research Institute, we've kicked off real-world research with the VA to collect additional data on how gammaCore performs after use among veterans, and what effect it might have on PTSD. One of the many VA research institutes across the country, the Dorn Institute focuses primarily on bettering clinical results and life quality for veterans. Our view is that this information will enable us to put together a framework for a wider indication covering mild traumatic brain injury and PTSD, moving gammaCore past being just a headache treatment and into the realm of neurological health. At the VA location we selected, gathering data for the real-world PTSD study is underway right now, and it links directly to what we're doing with Acacia. We'll share updates with you as this program moves forward. Third, regarding products, we've begun outlining the structure for our upcoming clinical device. The goal is a design that not only delivers vagal nerve stimulation but also captures biometrics. While we're just starting this work, we're aiming for a form factor users won't have to hold, one that gives real-time feedback in a closed-loop setup—something that could prove useful for grasping and addressing what each user or patient specifically requires. Now, the second catalyst: we plan to broaden our commercial customer base past the acceleration work we're doing within the VA. This covers: first, breaking into additional markets such as TAC-STIM with first responders — for example, a study using TAC-STIM during yearly SWAT training, plus other chances to support our first responders in their everyday duties, or to make headway with assorted domestic law and U.S. intelligence agencies; second, growing our Kaiser Permanente work beyond California, and federal channels including DoD and federal workers' compensation, via our newly dedicated 1099 and W-2 employee, respectively; and third, a fresh emphasis on advocacy inside the VA's Department of Women's Health, with help from members of our Board. The third catalyst on our list is what shows up in the numbers themselves: revenue growth picking up speed, lowering cost of sales so it represents roughly 54% of revenue by the end of 2027, cutting 3% from General & Administrative expenses related to transaction fees on sales outside our FSS contract, and steering toward positive adjusted EBITDA. We still expect operating leverage to get better as the sales infrastructure we've built out reaches maturity and VA revenue grows larger against a cost structure that stays mostly fixed. One last point on capital before I turn things over. We take a disciplined approach here. Growth, new indications, and new products are where we intend to direct capital — not just to cover operating burn. During Q2 of 2026, about one million dollars in cash went out the door for growth-related purposes. That included buying inventory so we'd have enough product for the sales we anticipate, making capital upgrades at our Rockaway site to ensure our infrastructure keeps pace with the expansion we're planning, and reorganizing our commercial team to speed up revenue. Staying disciplined like that, along with the portfolio's momentum and ten million dollars in cash sitting on the balance sheet, puts us in a strong position to grow revenue faster and shrink operating losses as we move through the back half of 2026. It also gives us confidence that we'll reach positive adjusted EBITDA in Q3 of 2027. With that said, I'd like to open things up for questions. Operator?

Jeffrey Cohen

analyst
#5

Alright, I've got a couple of things to ask. First off, could you help us understand the sales and marketing spend for the back half a bit more clearly, specifically regarding the ads? Take us through the ads once more, particularly on the sales force side. You mentioned 72 ads out of 1099. Do any ads appear on the W-2s, and could you explain how that ties into back half spending compared with the front half?

Josh Lev

executive
#6

Certainly. Mike, would you like to handle that one? Would you like to describe the adjustments you're making within the commercial organization?

Mike Fox

executive
#7

Yes, that sounds great. Sorry, I’m getting a little back. I don’t know if you can hear me back talk, but we’ll clear that up for you. Yes, Jeffrey, great question. As you know, 1099s, we pay a percent commission based on revenue. So the additive cost of those 1099s that I said in the discussion points were some of the best in the country. There’s no economic additions to that. That’s truly just a percent of revenue enhancement to our bottom line. The increase in our regional directors from three to six was an additive cost. However, a few of those were promotions internally because we have a very strong bench internally at the company. So there’s very little additional cost to that leadership change, in my opinion. It was a very smart investment and will be easily taken up by the increased revenue based on the focus.

Jeffrey Cohen

analyst
#8

My apologies for that. Now, to follow up, would you mind discussing peripheral neuropathy? Also, which trial do you expect to wrap up before this year ends? And after that, what's your timeline and the route you intend to take toward securing a broader label, if I have that right?

Josh Lev

executive
#9

Absolutely, that's an excellent question, Jeff. I really appreciate it, and I'm always grateful for your backing. Regarding our CIPN efforts, the work is in fact complete already. Back when we bought NeuroMetrix in 2025, a trial focused on Chemotherapy-Induced Peripheral Neuropathy had already been finished. Once we examined the market, we identified a substantial unmet need. One figure I recall is that about 70% of people undergoing chemotherapy develop some type of chemotherapy-induced peripheral neuropathy. So as we see it, no genuinely extra effort, strictly speaking, remains necessary from a clinical trial standpoint. What we're doing at this stage is simply arranging the data and putting it together in a manner that lets us move forward and file with the FDA prior to year's end. So looking at the total workload, we truly don't foresee needing any further data points at present. The main task is really assembling the material and collaborating with our FDA consultants so we can present it to the FDA as a broader label for the Quell product line.

Swayampakula Ramakanth

analyst
#10

I have a handful of things to ask. To start, prescription gammaCore revenue clearly was up 11% compared with the same quarter last year. But when I run the numbers quarter to quarter, it fell 4%. So of that slowdown, how much comes from the commercial reorganization you've either just wrapped up or are still working through, and how much reflects actual demand for the product at the account level? And when I look at the guidance again, it's above 30%, which implies you need to land near $23 million during the back half. What has to happen between now and then to reach that?

Josh Lev

executive
#11

Okay, RK, that's an excellent question. I really appreciate it; and once more, I truly appreciate you being with us today. From where we sit, if you look at the gammaCore slowdown, much of it is indeed tied to the shift into this new era, or the restructuring we're carrying out. Still, I'd say it has less to do with the specific changes implemented or with demand, and more to do with the fact that we're altering our KPIs and how we approach growing the business going forward. What I mean is that in the past, we enjoyed a very strong refill pipeline. With our refreshed emphasis and the new way we're beginning to view things, we're not focused solely on refills, but also on constructing that pipeline of upcoming new patient starts. So what I believe we witnessed this quarter was, first, a shift in philosophy, as our team starts moving some of its attention from prior activities toward what we want them to do going forward. Another point worth mentioning is that we experienced a single snag at one specific site in Phoenix involving the prosthetics department. Normally, that VA facility has about seven prosthetics agents processing orders. Due to resourcing problems, that figure dropped to one, which caused a backlog. As Mike mentioned, that represented approximately $145,000 in orders, and those have now been fulfilled, so they are set to be, or will be, recognized in Q3 revenue. But returning to your point, I believe you're asking about the slowdown. I'm not convinced that although it appeared on paper as a slowdown, it's truly more about philosophy and how we think about acceleration going forward, which naturally connects to your second question—where we expect that acceleration to originate. I'd say a big part of what you observed is the effort undertaken, correct, during this quarter to support acceleration ahead. We expect the changes we've implemented in the commercial team to start showing results during Q3 of 2023. Those changes include not just realigning territories, but also adding new 1099s, redesigning the incentive compensation plan, and focusing on a number of KPIs—including new ones—that we see as forward-looking signals of revenue growth. Also, if you take into account that growth rate above 30%, there are other places we've been putting more emphasis on. That push started around the latter part of Q2 and continues now in Q3, and it covers things such as TAC-STIM. Mike noted that we're ramping up what we're doing there, focusing especially on several kinds of federal agencies, including government-level statewide police departments as well as various intelligence organizations. So as part of growing that effort, Mike has brought on 17 additional 1099s — individuals he'd collaborated with previously — and a number of them bring role indexes plus know-how centered on selling into channels that were essentially new to us. Is there anything more you'd like to say on that point, Mike?

Mike Fox

executive
#12

Sure. Thank you, Josh. And it's precisely as you described. What I'd say to keep in mind, RK, is that in certain federal channels we aim to deliver as much steadiness as we can. However, my view is that it hinges on how stable the market is where you operate. The VA has consistently been one of those cases; expecting reliable quarter-over-quarter consistency from them is difficult, yet that 11% figure you brought up makes me incredibly proud. Since during our transition, if you grasp the price points for a few of the products we provide to the VA, as an illustration, gammaCore has a 90-day trial period to confirm the product performs properly, followed by a one-year option and a three-year option. Throughout this quarter, new patient starts have been quite robust amid the transition. What's different is that certain accounts in certain regions, rather than choosing a three-year prescription, have opted for the one-year prescription so they align better with their fiscal year budgets and also verify patients are responding well and can stay on therapy before committing to longer-term therapy. Therefore, this isn't a loss. It's genuinely a reshaping of the existing processes for treating patients with migraine and cluster headaches. Yet when we observe more patients receiving treatment from more providers and more accounts driving that figure, which is the aspect I notice that you at RK haven't had visibility into, I'm very pleased with what I observed. Would we prefer that figure to be larger? Certainly. But seeing it at 11%, the explanation comes very easily. The second aspect, regarding why we're excited about moving forward, is the capacity to enter these new accounts and achieve breadth and depth across so many different accounts, we can improve. Yet even more significantly, we have numerous providers across various departments, past neurology and past the headache clinics, who treat patients needing our help; we've brought people on board and are training our team to reach a greater level of expectations. And as Josh mentioned, there are opportunities outside the VA within the Department of Defense that are highly interesting. I attended a Department of Defense meeting just yesterday in D.C. And all I can say is the active military need us just as much as the VA does. So that's a key focus. I hope that provides you with a bit of clarity.

Swayampakula Ramakanth

analyst
#13

Great, though I'd like to pose one more batch of questions if I can. Over the years, we've grown accustomed to particular metrics that electroCore has provided. So here's a question about that; you did, after all, report 16,400 cumulative VA patients. I'm also attempting to grasp the facility count, plus utilization and reorder metrics — can you share any of that data during this call? And Mike, one of your mandates involved pursuing 75% consistent monthly utilization. What's the status there? And to what extent have you managed to get some of these folks genuinely focused on a metric like that?

Mike Fox

executive
#14

Josh, I can address your second question first. Yes, RK, excellent question. Perhaps a superior response would come from me territory by territory or account by account. Often, stabilization comes down to whether we've had the right people delivering the right message, since I genuinely believe in the three Ps — People, Process And Product. Our clinical data is exceptionally strong. At times, with 1099s, they weren't ranking us high enough among the products they sold; consequently, we weren't first or second in their bag. Priority time with priority customers wasn't coming our way. That's what our focus has been on; so sustaining more patients and more excitement truly means driving advocacy with the individual providers in the VA. That's where I'm witnessing the greatest results. We have instances of a few of the 1099s that entered accounts within just the last six to eight weeks, having moved from zero new patient starts to 12 new patient starts in six weeks simply because we have someone who understands the VA and understands access and how to reach the key advocates. We definitely have enough patients to take care of in the VA. They need us there. So hopefully, that offers you a bit more, but it's tough to say nationally what the one thing is, because I'd say the biggest part is the people and the expectations of performance that we're providing. Does that sound good?

Josh Lev

executive
#15

Right. And then, RK, regarding the overall count of facilities, what we aimed for this quarter wasn't actually to begin launching additional sites. The real objective was restructuring the team so we'd have a strategy in place going into Q3. As for how many new facilities we placed orders for, that figure stayed level compared with the prior quarter. But the other effort we genuinely began concentrating on involves this: we've publicly stated that we've sold to roughly 200 separate VA facilities that bought our products across the span of the past several years. Yet during the prior quarter, while working through this exercise, we observed that merely around one-third of those sites were truly centered on moving the Quell product. So a major priority for us during this specific quarter — Q2 — became figuring out how to broaden Quell's uptake among the accounts already buying from us, whether they'd purchased gammaCore or another item. What we did was revamp the training, the approach, and also the emphasis, I'd say, for certain sales executives inside our company, such that a number of them currently handle Quell exclusively rather than carrying both. Still, the larger takeaway is that our priority this quarter wasn't boosting how many facilities buy. What it truly was, is preparing things for Q3, pinpointing fresh targets across various territories. And once more, we now have 17 additional 1099s who will canvas various regions and various sites we don't yet have, plus drive greater Quell adoption among current accounts.

Swayampakula Ramakanth

analyst
#16

I've got a fast one about Quell. I do appreciate that you brought up Quell and the way you're handling it and attempting to expand those sales; along those lines, Quell sales were up more than 30% quarter over quarter. What gives you confidence that this kind of expansion will keep going? I realize the base sits at 1.3 million. That isn't a large base, but even so, how do you view growth in that area, as you build deeper ties inside every one of the VA facilities?

Josh Lev

executive
#17

Yeah. So I'll offer just my two cents, and then I'll hand it over to Mike so he can add whatever he thinks. But there are, I'd say, a few items. First, we're genuinely altering how we think about our sales organization and the way they sell various products and who is permitted to sell Quell and who is not permitted to sell Quell. That's the first one. Second, earlier in this call I noted that the overall market, per rheumatology advisers, was, I believe, approximately 2% of active duty military having some type of Fibromyalgia prior to deployment, and that figure rose to somewhere around 8% to 11% following deployment. This idea of drawing in or pursuing active duty military, I believe, represents a truly, truly big opportunity for the organization; historically we've really centered on the VA; yet the Quell product line on its own, if you consider it, truly doesn't have that many natural competitors in the bioelectronic therapeutics market space, particularly for various types of Fibromyalgia or Fibromyalgia broadly. So the reason that matters to us is that we've revamped our training regarding how we proceed to train for the Quell product line. In the past, we had one, let's call it, product expert. That product expert is now collaborating with the remainder of the new marketing team that was brought in, which Mike mentioned. on the resources and the training so that everybody can sell Quell, along with what I said earlier, unlocking a new genuine target market for us, namely active duty military, which isn't something we'd concentrated on previously. Mike, is there anything you'd like to add to that?

Mike Fox

executive
#18

Yes. RK, I was going to mention a few more quick points. Getting me to limit myself to just one thing is impossible. To start with Fibromyalgia, our enthusiasm comes from the fact that if you look back to when that company was bought, keep in mind it had been built to stand alone on Quell; and looking at the market, it could succeed as a product on its own. Having it as a second item in our armamentarium is fortunate for us. So in my view, this is a very exciting moment to have both products in the VA, especially Quell. Just for your information, Fibromyalgia in the old literature was referred to as chaos. Chronic hurts all over syndrome. That kind of treatment is needed by the VA, and a significant number of patients have unmet needs who are being medically treated but lack quality of life. So we have an opportunity to dive deep. I believe the biggest answer to your question about our focus relates to our example with the women's health department. Within the VA and active military, women have a very high rate of Fibromyalgia compared to their male counterparts. The same holds for migraines. But there's a large business within the VA focused on these type of ailments that we, as a company, had not aligned with as much as we should have before I entered the company; so we're focused on the right providers with the right therapy for the right patient. We do that. We're excited about the future with Quell.

Josh Lev

executive
#19

Fozia, let's turn to you next. Seems like you also have something you'd like to ask.

Fozia Ahmed

analyst
#20

I was just curious whether you could say more about how shifting to Lovell government services as your main federal supply schedule contract holder is going to make things better for its VA and DoD customers? And could you also go into what particular benefits this partnership will bring?

Mike Fox

executive
#21

Yes. Josh, would you like me to handle that, and then I'll hand it back to you for part of the contracting angle on it?

Josh Lev

executive
#22

Yeah, absolutely. Yeah.

Mike Fox

executive
#23

Fozia, that's a great question, because not many people realize how certain opportunities inside the FSS are different — for example, being able to contract and route your products via small to stable veteran-owned groups. The advantage is pretty clear. The VA has requested that a specific percentage of its business go through those entities; so we're aligning ourselves with what the VA and Department of Defense are looking for. But the most important thing for our company is that they're the specialists when it comes to essentially handling orders and maintaining harmony within the ordering systems in the federal space. It's not like our performance was poor, but when it comes to that particular task, those individuals are the true specialists. So having them choose us as their exclusive provider is a real stroke of luck. Beyond that, they bring capabilities to the table that our own FSS simply cannot match. There's something they call DAPA, along with ECAT, plus a web-based shop. On top of that, they offer numerous other avenues for assisting us with active-duty service members — places like military treatment facilities and the VAs. Their connections in Washington are substantial too, since they retain their own lobbying organization. This isn't merely a distribution arrangement; it functions as a genuine partnership. My past experience includes collaborating with Lovell Government Services through other organizations, and when it comes to pinpointing what veterans require and serving those in need of assistance, nobody in this country does it better. The economic rationale behind our choice is undeniable, but an additional motive was that it strengthens our company and supports our mission of serving the VA. Josh, if you'd care to chime in with anything further, the floor is yours.

Josh Lev

executive
#24

Yeah, I think — so, when it comes to the contracting side, and just looking at the whole economic picture, moving to Lovell is something we believe can genuinely help us improve margins. The main thing is how Lovell gets paid: usually there's a markup on the price we give the government. Why that matters is that when we sell directly through our own FSS contract, rebates get deducted, and we're obligated to pay those back to the customer. That's known as an IFF. That said, those rebates come entirely out of Lovell's economics. So we don't owe that. It's taken from their fee, meaning at the margin there's no extra cost for us, since we net the same amount we'd have netted before if we'd sold direct. What's different is that we retain the rebate. The second part — which I'd argue is even bigger — is that any time we bill a government, and I'm sure you know this, the government's prosthetics department generally gives us their credit card. Each transaction where we swipe a card costs about 3% on all direct sales. Again, with Lovell's fee, their fee, which is incremental, absorbs that 3%. Typically, if we fulfill an order through a direct arrangement using our own contract, we wind up returning the rebate and covering the transaction fee. But when we work directly with Lovell, we retain the entire amount, correct? That stays with us. So in my view, that's a financial advantage. The sole item I might label a "downside," if you choose to describe it that way, has to do with how quickly cash moves through our business and our receivables. In the past, our AR performance has been exceptionally strong. That's because we generally process the credit card first and ship afterward. When it comes to Lovell—and really any Lovell order—the process works like this: Lovell places the order with us, we send out the product, the VA reimburses Lovell, and after that Lovell reimburses us. Those additional one or two days are going to have an impact on how long our accounts receivable stay outstanding. That said, when it comes to paying us, Lovell has been extremely, extremely reliable, doing so far, far, far earlier than their obligations require, both for amounts that are current and those that aren't. And in our view, it won't really amount to a material change on the whole when it comes to growth in our AR balances. However, on the contracting side, that's really the sole modification I would classify as not "favorable." As far as this goes, all the rest represents a beneficial deal for the organization. Therefore, when you examine Lovell strictly from the standpoint of overall economics, it will prove more advantageous compared with going direct via our own FSS contract. Excellent. Thanks. Operator, are there further questions from anyone on the call? All right. It appears we have a question now from Jeremy Perlman. Jeremy's question is, you raised your full year revenue outlook from roughly 30% growth to more than 30%. Could you detail what's behind the greater confidence? Which of those is mainly driving the improvement — gammaCore with the VA, Quell, or Truvaga — or is it a mix of all three? Mike, would you like to take that question?

Mike Fox

executive
#25

Absolutely, Josh. That's a really good question, Jeremy. There's clearly a lot of enthusiasm around this. So what's driving it? I'd say it's everything you just listed. To give a bit more detail, the VA has consistently been a priority and will remain one for gammaCore as well as for Quell's expansion; we're eager about the paths ahead for both. But with the Department of Defense, when we talk about down range, we mean military treatment facilities. We're talking about first responders, the impact and the work we're doing at Kaiser, plus some new entrants, and people have been talking about possible TRICARE opportunities. I believe the main reason for the enthusiasm is that we aren't merely evaluating possibilities. We're looking at many different items as critical access discussions for the quarter that have begun producing real metrics and results. As we've said previously, we've received first responder orders from a number of SWAT teams. We have intelligence agencies placing orders for product. We do have military treatment facilities making their initial order within the last eight weeks. So we're seeing the payoff from our efforts. That's why the excitement exists. It isn't due to having nice ideas. We're beginning to see outcomes from what we've done; so that's what I'd say at this moment, that's the source of the excitement.

Josh Lev

executive
#26

Appreciate that, Mike. Jeremy here, picking up. The VA remains your number one channel for prescriptions. When it comes to the VA, is the growth coming from more usage at locations that already exist, from adding new sites, or from more patients being served at each site? Of those three, which one do you expect to drive the most over the coming quarters?

Mike Fox

executive
#27

Absolutely, Josh — I appreciate that, and honestly it might be my favorite one to respond to. Jeremy, the response is affirmative. What I'd say is this: the people are in place, our attention is locked in, and the offerings are there. So across the years, ever since gammaCore arrived, and more lately following the addition of Quell, we've reached a lot of VAs — yet what we still need is steady usage along with champions in additional accounts and with greater depth, and that's what we've observed through the subsequent stage that we brought in over the past 90 days. So indeed, we'll keep our attention there, since that will deliver the largest effect. My take is that once most VAs — a national majority — are using it, and a substantial count of providers are using the technology, I might feel reasonably pleased at that moment, though growth opportunities never disappear. Still, it takes both pieces together. We must spread the risk rather than let a handful of accounts hold big volume. More accounts need volume that lasts and stays steady, and that is where our attention sits today, and it will keep producing the largest returns. Over to you, Josh.

Josh Lev

executive
#28

Thank you, Mike. Okay. We've got the final question, and it comes from Jeremy. He wants to know whether investors ought to anticipate that incremental gross profit will progressively make its way down to the bottom line, or whether we plan to keep spending heavily on commercial expansion. Jeremy, that's yet another excellent question. What I'd say is that yes, we do anticipate incremental gross profit progressively reaching the bottom line. As revenue keeps growing, we anticipate that gross profit will keep dropping through, and we're observing operating margin coming out of our P&L. The greater the net sales we can bring in, the more we think will flow down to the bottom line. When it comes to gross margin, though, we keep directing both analysts and investors to build their models around an 85% gross profit margin. We think that figure can be sustained, certainly across the short to midterm. That's the guidance we'd give to the analysts, correct? So we hold that essentially constant. Then, on the matter of spending heavily on commercial expansion, I believe Mike has covered a great deal of that during roughly the past hour on this call. We've undertaken many steps throughout this quarter to guide us into this new era, and quite a bit of commercial expansion is underway, both when it comes to our current customer accounts and when it comes to the various areas through which we think we can demonstrate that expansion. That covers everything from federal marketplaces, federal workers' comp, the TAC-STIM illustrations Mike provided earlier across various state police departments, SWAT, various intelligence, federal intelligence agencies. And finally, of course, drawing on the data and the product success we've enjoyed with Quell and delivering that, along with gammaCore, to our active duty military. So with that, the question-and-answer portion of the earnings call is now finished. I'm grateful for everyone's time today. Thank you to all our shareholders for your patience and your continued support. And then, of course, above all, to our team: thank you for turning up daily with discipline and the ambition to help us carry out the strategy and truly do what's needed to help us reach our goals and meet the ambition that the opportunity before us requires. So with that, we're grateful for everyone joining today's call, and we look forward to talking with you again next quarter. With that, our earnings call is now finished. Thank you, everyone, and have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete electroCore, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to electroCore, Inc. earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in electroCore, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.